Abbott Laboratories' Indian arm, marketing branded pharma, vaccines & nutritionals across 6 therapy areas
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 2.4k | 2.6k | 2.8k | 3.2k | 3.7k | 4.2k | 4.0k | 4.8k |
| Borrowings | 175 | 153 | 152 | 113 | 83 | 197 | 182 | 172 |
| Other Liabilities | 940 | 1.1k | 1.3k | 1.3k | 1.4k | 1.5k | 1.5k | 1.6k |
| Total Liabilities | 3.5k | 3.8k | 4.2k | 4.6k | 5.2k | 5.9k | 5.7k | 6.5k |
| AssetsFixed Assets | 270 | 251 | 271 | 237 | 225 | 336 | 314 | 331 |
| CWIP | 2 | 1 | 1 | 4 | 10 | 18 | 23 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 3.3k | 3.6k | 4.0k | 4.3k | 5.0k | 5.6k | 5.4k | 6.2k |
| Total Assets | 3.5k | 3.8k | 4.2k | 4.6k | 5.2k | 5.9k | 5.7k | 6.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 499 | 626 | 727 | 948 | 893 | 1.2k | 1.0k | 1.3k |
| Cash from Investing | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 |
| Cash from Financing | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1.1k |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 504 | 611 | 704 | 904 | 860 | 1.2k | 960 | 1.3k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (47.4×) and current (38.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 17.8% growth and a 38× exit, ₹28055 only delivers your return if you pay ₹28,075. The price is currently baking in 18% growth.
EPS grows 17.8%/yr for 5 years, then fades to 6% over 2, exits at 38×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 17.8% | 860.41 |
| FY28 | 17.8% | 1013.56 |
| FY29 | 17.8% | 1193.98 |
| FY30 | 17.8% | 1406.51 |
| FY31 | 17.8% | 1656.87 |
| FY32 | 11.9% ·fade | 1854.03 |
| FY33 | 6.0% ·fade | 1965.27 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.